Diabetes medications with cardiovascular protection in the wake of EXSCEL: Is there a class effect for long-acting GLP-1 receptor agonists?

Robert E.J. Ryder; Ralph A. Defronzo

doi:10.15277/bjd.2017.147

Diabetes medications with cardiovascular protection in the wake of EXSCEL: Is there a class effect for long-acting GLP-1 receptor agonists?

Robert E.J. Ryder
, Ralph A. Defronzo

Division of Diabetes

Producción científica: Review article › revisión exhaustiva

3 Citas (Scopus)

Idioma original	English (US)
Páginas (desde-hasta)	131-133
Número de páginas	3
Publicación	British Journal of Diabetes and Vascular Disease
Volumen	17
N.º	4
DOI	https://doi.org/10.15277/bjd.2017.147
Estado	Published - 2017

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Acceder al documento

10.15277/bjd.2017.147

Otros archivos y enlaces

Citar esto

@article{afb0a55e7a3847b2abf8a6fa9d7cf627,

title = "Diabetes medications with cardiovascular protection in the wake of EXSCEL: Is there a class effect for long-acting GLP-1 receptor agonists?",

author = "Ryder, \{Robert E.J.\} and Defronzo, \{Ralph A.\}",

year = "2017",

doi = "10.15277/bjd.2017.147",

language = "English (US)",

volume = "17",

pages = "131--133",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Diabetes medications with cardiovascular protection in the wake of EXSCEL

T2 - Is there a class effect for long-acting GLP-1 receptor agonists?

AU - Ryder, Robert E.J.

AU - Defronzo, Ralph A.

PY - 2017

Y1 - 2017

UR - https://www.scopus.com/pages/publications/85039935446

UR - https://www.scopus.com/pages/publications/85039935446#tab=citedBy

U2 - 10.15277/bjd.2017.147

DO - 10.15277/bjd.2017.147

M3 - Review article

AN - SCOPUS:85039935446

SN - 1474-6514

VL - 17

SP - 131

EP - 133

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

IS - 4

ER -